Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy

-- Polymer-conjugated IL-15 (NKTR-255) induced CD8+ T cell and natural killer cell proliferation in vivo -- -- NKTR-255 enhanced the efficacy of human CD19 CAR-T cells in a xenogeneic lymphoma model -- SAN FRANCISCO, Nov. 9, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today...

Click to view original post